Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
To require online marketplaces to verify certain information regarding high-volume third party sellers of consumer products on such online marketplaces and to disclose to consumers certain contact and other information regarding such high-volume third party sellers.
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
WALGREEN COMPANY via WALGREEN COMPANY
2022 · first_quarter · Q1
S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues. Issues related to corporate tax rate and other international tax provisions in Build Back Better Act (H.R.5376).
To require online marketplaces to verify certain information regarding high-volume third party sellers of consumer products on such online marketplaces and to disclose to consumers certain contact and other information regarding such high-volume third party sellers.
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
S. 936: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
S. 936: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
S. 936: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act. S.2543, The Prescription Drug Pricing Reduction Act of 2019; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. H.R. 6573, Help Our Heroes Access Medicine Act of 2020; issues related to pharmacy co-pays.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act. S.2543, The Prescription Drug Pricing Reduction Act of 2019; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. H.R. 6573, Help Our Heroes Access Medicine Act of 2020; issues related to pharmacy co-pays.
Help Our Heroes Access Medicine Act of 2020
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act. S.2543, The Prescription Drug Pricing Reduction Act of 2019; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. H.R. 6573, Help Our Heroes Access Medicine Act of 2020; issues related to pharmacy co-pays.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act. S.2543, The Prescription Drug Pricing Reduction Act of 2019; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. H.R. 6573, Help Our Heroes Access Medicine Act of 2020; issues related to pharmacy co-pays.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H.R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H.R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H. R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
Prescription Drug Pricing Reduction Act of 2019
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act. S.2543, The Prescription Drug Pricing Reduction Act of 2019; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. H.R. 6573, Help Our Heroes Access Medicine Act of 2020; issues related to pharmacy co-pays.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H.R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H.R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H. R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency.
Amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients related to opioid risk factor reduction and opioid antagonist counseling; no legislation. H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing "Out-of-Pocket" costs to seniors.
H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing "Out-of-Pocket" costs to seniors.
H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. S.B. 2543 (Prescription Drug Pricing Reduction Act of 2019) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. H.R. 3 (The Elijah E. Cummings Lower Drug Costs Now Act) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors.
H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. S.B. 2543 (Prescription Drug Pricing Reduction Act of 2019) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. H.R. 3 (The Elijah E. Cummings Lower Drug Costs Now Act) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1 - The "Tax Cuts and Jobs Act." Impact of corporate tax reform on Walgreens business operations.
H.R. 10 - The Financial CHOICE Act, all provisions related to debit swipe fee reforms
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 109 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 109 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Comprehensive Addiction and Recovery Act of 2016
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 524 - the "Comprehensive Addiction and Recovery Act of 2015," all provisions regarding combatting opioid addiction and abuse
Comprehensive Addiction and Recovery Act of 2016
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 524 - the "Comprehensive Addiction and Recovery Act of 2015," all provisions regarding combatting opioid addiction and abuse
Comprehensive Addiction and Recovery Act of 2016
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 524 - the "Comprehensive Addiction and Recovery Act of 2015," all provisions regarding combatting opioid addiction and abuse
Protecting the Integrity of Medicare Act of 2015
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Protecting the Integrity of Medicare Act of 2015
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Protecting the Integrity of Medicare Act of 2015
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
To improve cybersecurity in the United States through enhanced sharing of information about cybersecurity threats, and for other purposes.
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S.754 - the Cybersecurity Information Sharing Act of 2015, all provisions related to liability protection for electronic sharing of cyber threat indicators with the federal government.
Medication Therapy Management Empowerment Act of 2015
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Medication Therapy Management Empowerment Act of 2015
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Medication Therapy Management Empowerment Act of 2015
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Medication Therapy Management Empowerment Act of 2013
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
Medication Therapy Management Empowerment Act of 2013
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
Medication Therapy Management Empowerment Act of 2013
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
Medication Therapy Management Empowerment Act of 2013
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.
Client: WALGREEN COMPANY · Firm: WALGREEN COMPANY
H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
2021 · fourth_quarter · Q4
S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues. Issues related to corporate tax rate and other international tax provisions in Build Back Better Act (H.R.5376).
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2021 · third_quarter · Q3
S. 936: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues. Issues related to corporate tax rate and other tax provisions in The American Jobs Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2021 · second_quarter · Q2
S. 936: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Issues related to pharmacy provider status. H.R. 3554 / S. 1909, issues related to direct and indirect remuneration fees in Medicare.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues. Issues related to corporate tax rate and other tax provisions in The American Jobs Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2021 · first_quarter · Q1
S. 936: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.
Issues related to pharmacy provider status. Issues related to direct and indirect remuneration fees in Medicare.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues. Issues related to corporate tax rate and other tax provisions in The American Jobs Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2020 · fourth_quarter · 4A
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues.
Issues related to pharmacy provider status. Issues related to direct and indirect remuneration.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H.R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
WALGREEN COMPANY via WALGREEN COMPANY
2020 · fourth_quarter · Q4
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H.R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
Issues related to pharmacy provider status. Issues related to direct and indirect remuneration.
WALGREEN COMPANY via WALGREEN COMPANY
2020 · third_quarter · Q3
Issues related to pharmacy provider status.
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency. H. R. 7756: To require online marketplaces to verify and disclose certain information regarding high-volume third-party sellers of consumer products to inform consumers.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2020 · second_quarter · Q2
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act. S.2543, The Prescription Drug Pricing Reduction Act of 2019; issues related to pharmacy, pharmacist provider status, and Medicare reimbursement. H.R. 6573, Help Our Heroes Access Medicine Act of 2020; issues related to pharmacy co-pays.
WALGREEN COMPANY via WALGREEN COMPANY
2020 · first_quarter · Q1
S. 3431: INFORM Consumers Act; provisions related to online marketplace transparency.
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income.
Issues related to pharmacy, pharmacist provider status, and taxes in H.R. 748 - the CARES Act (Pub.L. 116-136), H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116 -127), H.R. 6379 - Take Responsibility for Workers and Families Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
WALGREEN COMPANY via WALGREEN COMPANY
2019 · fourth_quarter · Q4
H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. S.B. 2543 (Prescription Drug Pricing Reduction Act of 2019) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors. H.R. 3 (The Elijah E. Cummings Lower Drug Costs Now Act) provisions related to lowering drug prices and reducing Out-of-Pocket costs to seniors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2019 · third_quarter · Q3
Issues related to data privacy and HIPAA modernization; no legislation.
H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing "Out-of-Pocket" costs to seniors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2019 · second_quarter · Q2
Issues related to data privacy and HIPAA modernization; no legislation.
Amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients related to opioid risk factor reduction and opioid antagonist counseling; no legislation. H.R. 1034 and S.B. 640 (the Phair Pricing Act); provisions related to lowering drug prices and reducing "Out-of-Pocket" costs to seniors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2019 · first_quarter · Q1
Amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients related to opioid risk factor reduction and opioid antagonist counseling; no legislation. Issues related to lowering drug prices and reducing "Out-of-Pocket" costs to seniors; no legislation.
Issues related to data privacy and HIPAA modernization; no legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2018 · fourth_quarter · Q4
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2018 · third_quarter · Q3
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2018 · second_quarter · Q2
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2018 · first_quarter · Q1
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 - The Every Prescription Conveyed Securely Act. The bill would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2017 · fourth_quarter · Q4
H.R. 1 - The "Tax Cuts and Jobs Act." Impact of corporate tax reform on Walgreens business operations.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2017 · third_quarter · Q3
Issues related to corporate tax reform; no legislation.
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 - The "Every Prescription Conveyed Securely Act." The bill would amend title XVIII of the Social Security Act to require e-prescribing under part D of the Medicare program of prescription drugs that are controlled substances.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2017 · second_quarter · Q2
H.R. 10 - The Financial CHOICE Act, all provisions related to debit swipe fee reforms
Issues related to corporate tax reform; no legislation.
Proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
WALGREEN COMPANY via WALGREEN COMPANY
2017 · first_quarter · Q1
Proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
S. 109 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Issues related to corporate tax reform; no legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2016 · fourth_quarter · Q4
Issues related to corporate tax reform; no legislation.
Proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2016 · third_quarter · Q3
Proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
S. 524 - the "Comprehensive Addiction and Recovery Act of 2015," all provisions regarding combatting opioid addiction and abuse
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
WALGREEN COMPANY via WALGREEN COMPANY
2016 · second_quarter · Q2
Issues related to corporate tax reform; no legislation.
Proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
S. 524 - the "Comprehensive Addiction and Recovery Act of 2015," all provisions regarding combatting opioid addiction and abuse
WALGREEN COMPANY via WALGREEN COMPANY
2016 · first_quarter · Q1
Proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
S. 524 - the "Comprehensive Addiction and Recovery Act of 2015," all provisions regarding combatting opioid addiction and abuse
WALGREEN COMPANY via WALGREEN COMPANY
2015 · fourth_quarter · Q4
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Antitrust/Merger Issues; no legislation. Issues related to the proposed transaction between Walgreens Boots Alliance and Rite Aid; no legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2015 · third_quarter · Q3
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Issues related to fraud, waste and abuse prevention in Medicare Part D; no legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2015 · third_quarter · RA
Issues relating to retail pharmacy.
Issues relating to retail pharmacy.
Issues relating to retail pharmacy.
WALGREEN COMPANY via WALGREEN COMPANY
2015 · second_quarter · Q2
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
S.754 - the Cybersecurity Information Sharing Act of 2015, all provisions related to liability protection for electronic sharing of cyber threat indicators with the federal government.
WALGREEN COMPANY via WALGREEN COMPANY
2015 · first_quarter · Q1
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2015 · first_quarter · 1A
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.
H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN COMPANY via WALGREEN COMPANY
2014 · fourth_quarter · Q4
S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.
H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
WALGREEN COMPANY via WALGREEN COMPANY
2014 · third_quarter · Q3
Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
WALGREEN COMPANY via WALGREEN COMPANY
2014 · second_quarter · Q2
H.R.4069 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2013," all provisions related to changes to the registration process under the Controlled Substances Act and the establishment of the Combatting Prescription Drug Abuse Working Group.
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
WALGREEN COMPANY via WALGREEN COMPANY
2014 · first_quarter · Q1
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
WALGREEN COMPANY via WALGREEN COMPANY
2013 · fourth_quarter · Q4
S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist federally in health care delivery. No specific legislation
WALGREEN COMPANY via WALGREEN COMPANY
2013 · third_quarter · Q3
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist in health care delivery. No specific legislation
S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
WALGREEN COMPANY via WALGREEN COMPANY
2013 · second_quarter · Q2
S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.
WALGREEN COMPANY via WALGREEN COMPANY
2013 · first_quarter · Q1
S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.
Issues related to pharmacy prescription compounding and Food and Drug Administration oversight. No legislation.
WALGREEN COMPANY via WALGREEN COMPANY
2012 · fourth_quarter · Q4
H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales. Issues related to corporate tax reform. No specific legislation.
H.R. 436 - the "Health Care Cost Reduction Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin.
WALGREEN COMPANY via WALGREEN COMPANY
2012 · third_quarter · Q3
H.R. 436 - the "Health Care Cost Reduction Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. H.R. 5853 - the "Gray Market Drug Reform and Transparency Act of 2012," all provisions regarding making it a prohibited act and a misbranding for wholesale distributor of prescription drugstore purchase or receive a prescription drug from a pharmacy or pharmacist.
H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.
WALGREEN COMPANY via WALGREEN COMPANY
2012 · second_quarter · Q2
S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.
WALGREEN COMPANY via WALGREEN COMPANY
2012 · first_quarter · Q1
H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.
H.R. 2529/S.1368 - the "Restoring Access to Medication Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limits payments for medications from health savings accounts, medical savings accounts, and health felxible spending arrangements to only prescriotion drugs or insulin.
WALGREEN COMPANY via WALGREEN COMPANY
2011 · fourth_quarter · Q4
H.R.1540/S. 981- the "National Defense Authorization Act of FY 2012" - provisions related to the TRICARE pharmacy program. TRICARE-no specific legislation-regarding pharmacy services provided to TRICARE beneficiaries. H.R. 1971- the "Pharmacy Competition and Consumer Choice Act of 2011"- all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026- the "Safeguarding America's Pharmaceutical Act."-all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584- the "Drug Safety and Accountability Act"- all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.
WALGREEN COMPANY via WALGREEN COMPANY
2011 · third_quarter · Q3
S. 575- the "Debit Interchange Fee Study Act of 2011"- all provisions regarding studying the market and appropriate regulatory structure for electronic debit card transactions. HR. 1081- the "Consumers Payment System Protection Act" -all provisions regarding delaying the implementation of proposed or final rules issued under the authority of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the reasonable and proportional fees and rules for electronic debit transactions. H.R. 2010/ S. 1098-the "Family and Retirement Health Investment Act of 2011"- provisions related to payments from a HSA for prescription and over-the-counter medicine or drugs.
S. 274- the "Medication Therapy Management Empowerment Act of 2011" -all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891-the "Medication Therapy Management (MTM) Benefits Act of 2011"-all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936- the "Medicare Access to Diabetes Supplies Act of 2011" -provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203- the "Medicare Home Infusion Therapy Coverage Act"- provisions related to the Medicare coverage of home infusion therapy and home infusion drugs.
WALGREEN COMPANY via WALGREEN COMPANY
2011 · second_quarter · Q2
H.R. 2- the "Repealing the Job Killing Health Care Law Act"- any discussions or provisions regarding Average Manufacturer's Price (AMP) and medication therapy management (MTM). H.R. 2267/S. 227- the "Home Health Care Planning Improvement Act"- provisions related to payments for home health care services. H. Res. 9- the "Replace" bill- all provisions regarding the instruction of certain committees to report legislation replacing the job-killing health law, specifically with regards to discussions of Average Manufacturer's Price (AMP) and medication therapy management (MTM). H.R. 5-the "Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011"-all provisions regarding capping damages at the greater of $250,000 or double the award of economic damages for certain health providers. H.R. 605/S. 312-the "Patient Freedom to Choose Act"-all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that restrict payments from health flexible spending arrangements for medications to prescription drugs and insulin. H.R. 2010/ S. 1098-the "Family and Retirement Health Investment Act of 2011"- provisions related to payments from a HSA/FSA for prescription and over-the-counter medicine or drugs. P.L. 111-148- the "Patient Protection and Affordable Care Act."-regarding the implementation of regulations of P.L. 111-148 including issues related to Average Manufacturer's Price (AMP), Medication Therapy Management (MTM), and employer coverage mandates.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income, and other tax issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amendment the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to corporate tax reform; no legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to retail pharmacy.
Issues relating to retail pharmacy.
Issues relating to retail pharmacy.
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.
H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.
H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.4069 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2013," all provisions related to changes to the registration process under the Controlled Substances Act and the establishment of the Combatting Prescription Drug Abuse Working Group.
Issues related to United States corporate tax reform - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.
S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.
S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.
S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. Issues related to related to pharmacists recognized as health care providers federally. No specific legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.Issues related to related to pharmacists recognized as health care providers federally. No specific legislation Issues related to Pharmacy Benefit Managers (PBM) activities around disclosures and audit protections. No legislation.
S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescription drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 6638, the Supporting Access to Formulated and Effective (SAFE) Compounded Drugs Act, all provisions requiring compounding pharmacies to register their facility with the FDA, requiring compounded drugs to be labeled appropriately, establishing an FDA database on compounding pharmacies and having the FDA set minimum production standards. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.
S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. Issues relating to Medicares Competitive Bidding program that includes mail order/retail-provided diabetic testing supplies with regards to reimbursements provided to retail pharmacies. No specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. Issues relating to Medicares competitive bidding program that includes mail order/retail-provided diabetic testing supplies with regards to reimbursements provided to retail pharmacies. No specific legislation.
H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.
HR 4223/S 1002 - the "SAFE DOSES Act," all provisions regarding embezzling, stealing, obtaining by fraud or deception, or knowingly and unlawfully taking, carrying away, or concealing a medical prduct that has not yet been made available for retail purchase by a consumer.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit the PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan, or to control the costs of such coverage, unless the manager satisfies specified PBM audit and disclosure requirements. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.
H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.
H.R. 2529/S.1368 - the "Restoring Access to Medication Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limits payments for medications from health savings accounts, medical savings accounts, and health felxible spending arrangements to only prescriotion drugs or insulin. H.R. 5651 - the FDA Reform Act of 2012, all provisions regarding reauthorizing and establishing new FDA prescription drug user-fee programs and revises requirements related to prescription, pediatric and generic drugs; medical devices; biosimilar biological products; new infectious disease drugs and drug manufacturer reporting. H.R. 5842 - the Restoring Access to Medication Act, all provisions regarding repealing provisions of PPACA that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. H.R. 436 - the Health Care Cost Reduction Act, all provisions regarding repealing provisions of PPACA that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. S.3187/S.2516 - the FDA Safety and Innovation Act, all provisions regarding reauthorizing and establishing new FDA prescription drug user-fee programs and revises requirements related to prescription, pediatric and generic drugs; medical devices; biosimilar biological products; new infectious disease drugs and drug manufacturer reporting.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," all provisions regarding requiring each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under each plan. H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites.
S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available. P.L. 111-148 - the "Patient Protection and Affordable Care Act," all provisions regarding the implementation of regulations of P.L. 111-148, including issues related to Average Manufacturer's Price (AMP), Medication Therapy Management (MTM), employer coverage mandates, pilot programs and demonstration projects.
No Legislation: Consumer protection advocacy in opposition to the merger of Express Scripts, Inc. and Medco Health Solutions, Inc.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 274- the "Medication Therapy Management Empowerment Act of 2011" -all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891- the "Medication Therapy Management (MTM) Benefits Act of 2011" - all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM in Medicare Part D benefit. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011" - provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act" - provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011" - all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.
H.R. 605/S. 312-the "Patient Freedom to Choose Act"-all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that restrict payments from health flexible spending arrangements for over-the-counter medications.
H.R. 3179 - the "Market Place Equity Act of 2011" - all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act" - all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.
H.R. 2010/S. 1098 - the "Family and Retirement Health Investment Act of 2011" - provisions related to payments from HSA for prescription and over-the-counter medicine or drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R.1540/S. 981- the "National Defense Authorization Act of FY 2012"- provisions related to the TRICARE pharmacy program. TRICARE-no specific legislation-regarding pharmacy services provided to TRICARE beneficiaries. H.R. 1971- the "Pharmacy Competition and Consumer Choice Act of 2011"- all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026- the "Safeguarding America's Pharmaceutical Act."-all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584- the "Drug Safety and Accountability Act"- all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.
H.R. 2267/S. 227- the "Home Health Care Planning Improvement Act"- provisions related to payments for home health care services. H.R. 5-the "Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011"-all provisions regarding capping damages at the greater of $250,000 or double the award of economic damages for certain health providers. H.R. 605/S. 312-the "Patient Freedom to Choose Act"-all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that restrict payments from health flexible spending arrangements for medications to prescription drugs and insulin.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 575- the "Debit Interchange Fee Study Act of 2011"- all provisions regarding studying the market and appropriate regulatory structure for electronic debit card transactions. HR. 1081- the "Consumers Payment System Protection Act" -all provisions regarding delaying the implementation of proposed or final rules issued under the authority of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the reasonable and proportional fees and rules for electronic debit transactions.
S. 274- the "Medication Therapy Management Empowerment Act of 2011" -all provisions regarding amending the Medicare Modernization Act to expand eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 1936- the "Medicare Access to Diabetes Supplies Act of 2011" -provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203- the "Medicare Home Infusion Therapy Coverage Act"- provisions related to the Medicare coverage of home infusion therapy and home infusion drugs.
Drug safety-no specific legislation-regarding any discussions surrounding the security of the drug supply chain. H.R.1540/S. 981- the "National Defense Authorization Act of FY 2012"- provisions related to the TRICARE program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE